Skip to main content
. Author manuscript; available in PMC: 2010 Jan 29.
Published in final edited form as: Cancer Chemother Pharmacol. 2008 Mar 5;63(1):65. doi: 10.1007/s00280-008-0712-z

Table 5.

Average pharmacokinetic values for PI-88 from 106 to 250 mg subcutaneous on day 1 in the presence of Docetaxel 30 mg/m2 intravenous once weekly

Average pharmacokinetic values for
PI-88 when administered with
docetaxel (30 mg/m2 IV weekly for 3 out of 4 weeks)		 PI-88 106 mg
subcutaneous
once daily dosing
(n = 3 patients)		 PI-88 140 mg
subcutaneous
once daily dosing
(n = 3 patients)		 PI-88 190 mg
subcutaneous
once daily dosing
(n = 3 patients)		 PI-88 250 mg
subcutaneous
once daily dosing
(n = 7 patients)
V/F (Volume of distribution/bioavailability) in mL 8,296 ± 3,150 11,811 ± 1,856 12,855 ± 4,618 14,261 ± 4,338
AUC (Area under the Concentration Curve) in h *ug/mL 47 ± 10 55 ± 12 147 ± 113 132 ± 51
T1/2 (half-life) in h 2.5 ± 0.6 3.1 ± 0.3 7.0 ± 5.9 5.2 ± 2.7
Tmax (time to maximal concentration) in h 2.3 ± 0.4 1.1 ± 0.8 2.4 ± 1.2 3.0 ± 1.4
C max (maximal concentration) in ug/mL 6.9 ± 2.1 9.7 ± 3.7 10.7 ± 3.5 11.1 ± 1.3
CL/F (Clearance/bioavailability) in mL/h 2,337 ± 489 2,626 ± 534 1,783 ± 960 2,156 ± 828